Aug 11, 2025 | News
Calgary, Alberta, Canada, August 11, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of...
Apr 30, 2025 | News
Calgary, Alberta – April 30, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the second final data set from its preclinical Rett...
Apr 16, 2025 | News
Calgary, Alberta – April 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL, OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together “Marvel”), are pleased to announce their acceptance to give an oral presentation at the International Rett...
Apr 14, 2025 | News
Calgary, Alberta – April 14, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), is pleased to announce that it has been invited to present its latest research...
Mar 28, 2025 | News
Calgary, Alberta, Canada, March 28, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that, subject to approval of the TSX Venture Exchange...
Mar 17, 2025 | News
Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and...
